Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Pathology|August 16, 2014
Aberrations of MYC are a common event in B-cell prolymphocytic leukemiaEllen Flatley, Andy I Chen, Xiangrong Zhao, et al.
Transplantation and Cellular Therapy|October 1, 2022
Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA StudyNathan Hale Fowler, Michael Dickinson, Monalisa Ghosh, et al.
Leukemia & Lymphoma|December 5, 2017
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphomaAndy I Chen, Jessica T Leonard, Craig Y Okada, et al.
The Lancet. Oncology|May 19, 2019
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 studyHervé Tilly, Franck Morschhauser, Nancy L Bartlett, et al.
Blood|September 30, 2018
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseCraig H Moskowitz, Jan Walewski, Auayporn Nademanee, et al.
Oncotarget|June 21, 2019
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Oncotarget|March 22, 2018
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
Blood Advances|December 12, 2022
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndromeShakthi T Bhaskar, Vivek G Patel, David L Porter, et al.
Blood Advances|December 10, 2024
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysisPeter A Riedell, Connor B Grady, Loretta J Nastoupil, et al.
Pageof 4